

Avantor 2022 performance snapshot

We serve customers across three geographic regions, in four end markets:



Biopharma



Advanced Technologies
& Applied Materials



Education &
Government



Healthcare

FULL YEAR

6.0¹%

Core organic
revenue growth

~110²bps

Adjusted EBITDA
margin expansion

\$710²M

Free cash flow

\$7.5B

Reported revenue

AMERICAS

\$4.5B

Reported revenue

6.1¹%

Core organic
revenue growth

EUROPE

\$2.5B

Reported revenue

5.5¹%

Core organic
revenue growth

AMEA

\$525M

Reported revenue

7.0¹%

Core organic
revenue growth

¹See "Non-GAAP Financial Measures" for a discussion and a calculation of non-GAAP measures.

²See "Reconciliations of non-GAAP measures" in our annual report on Form 10-K for a discussion and calculation of non-GAAP measures.

³Based on management estimates.

⁴Based on FY 2022 results.

⁵Management estimate based on pipeline value Jan. 2020 – Dec. 2022.

⁶Absolute reduction of scope 1 and scope 2 greenhouse gas emissions vs. 2019 baseline.

Well-positioned for growth

Extensive regulatory expertise

800+

Master Access Files

>\$80B

total addressable market³

>55%

of revenue from proprietary content

Broad portfolio – over

6M

products and services

Global footprint offers extraordinary customer access

~70%

of revenue from Life Sciences⁴

15%

GHG target reduction⁶



5x

increase in bioproduction innovation pipeline⁵

Global scale – serving over

300k

customer locations

>3,700

sales professionals

No single customer represents more than

5%

of our revenue